Accordingly, the identification of novel small molecules that are able to rescue the activity of the mutant CFTR remains of high relevance for designing improved pharmacological strategies to treat the fundamental cause of CF [46,47]. The gene discussed is CFTR; the disease is cystic fibrosis.